Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05075928

Acronym

LA-COVID

Enrollment

100

Registered

2021-10-13

Start date

2020-06-01

Completion date

2021-11-30

Last updated

2021-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-COV-2

Keywords

SARS-COV-2, Covid-19, Antiphospholipid syndrome (APS), autoimmune disease, antiphospholipid antibodies (aPL), thrombosis

Brief summary

SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis The objective of this study is to describe the diagnosis of thrombotic complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or aPL and the associated clinical and biological elements that may have favored thrombosis.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adult patient (≥18 years old) * Patient taken care of in the SMO pole or the NHC surgical resuscitation service or hospitalized or consultant to the HUS between 01/03/2020 and 31/05/2020 * Patient infected with Covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment * or Patient infected with Covid-19, with a documented infection, without documented thrombosis (arterial or venous), with in the standard work-up an increase in TCA revealing the presence of LA * Subject having given his agreement for the reuse of his data for the purposes of this research

Exclusion criteria

* Subject having expressed opposition to participating in the study * Subject under guardianship or guardianship * Subject under safeguard of justice

Design outcomes

Primary

Measure	Time frame
Retrospective study of thrombotic complications in a cohort of COVID patients with a circulating anticoagulant	Files analysed retrospectively from March 01, 2020 to May 31, 2019 will be examined]

Countries

France

Contacts

Primary ContactAnne-Sophie Korganow, MD, PhD

Anne-sophie.Korganow@chru-strasbourg.fr33 3 69 55 05 21

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr

Outcome results